Bio-Path Holdings, Inc. ( BPTH )  shares are falling on Friday.

The company reported fourth-quarter earnings per share of $4.23 loss, narrower than the estimate of $5.40 loss. 

Bio-Path ( BPTH ) reported a net loss of $33.63 per share for the year ended Dec. 31, 2023, lower than $38.12 per share in the year-ago period.

Research and development expense for the full year increased to $11.6 million, compared to $9.2 million in the year-ago period.

As of Dec. 31, 2023, the company had cash of $1.1 million, compared to $10.4 million as of Dec. 31, 2022. 

In December, Bio-Path ( BPTH ) announced the completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002, evaluating the ability of BP1002 for the treatment of refractory/relapsed lymphoma and refractory/relapsed CLL patients.

“As we look to the months and year ahead, we expect to build on the clinical progress achieved to date to bring potentially life-saving new medicines to patients battling cancers,” Bio-Path ( BPTH ) CEO Peter Nielsen said.

Price Action: BPTH shares are trading lower by 4.98% to $5.920 on the last check Friday.

Read Next: Taiwan Semiconductor Manufacturing Stock Is Up Over 5% – What’s Going On?